Ezekowitz Justin A, Théroux Pierre, Chang Weiching, Mahaffey Kenneth W, Granger Christopher B, Weaver W D, Hochman Judith S, Armstrong Paul W
University of Alberta, Edmonton, Canada.
Can J Cardiol. 2006 Apr;22(5):393-7. doi: 10.1016/s0828-282x(06)70924-2.
While natriuretic peptides have demonstrated diagnostic and prognostic potential in cardiac disorders, little is known about their relationship with the onset and quantification of myocardial infarction. The relationship of serial N-terminal pro-brain natriuretic peptide (NT-proBNP) with duration from symptom onset, infarct size and prognosis in ST elevation myocardial infarction (STEMI) patients treated with primary percutaneous intervention was examined.
Three hundred thirty-one STEMI patients in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial, which evaluated pexelizumab versus placebo, were studied. NT-proBNP (pg/mL) was measured at randomization, 24 h and 72 h; creatine kinase-MB area under the curve was measured at 72 h; and QRS score was assessed at discharge. Prognosis was ascertained from the 90-day composite clinical outcome of death, shock, stroke and congestive heart failure. Multivariate logistical regression was used to adjust for baseline characteristics for models at randomization, 24 h and 72 h. NT-proBNP was higher in patients with longer time from symptom onset (P<0.001) and correlated with measures of infarct size, including the area under the curve (P<0.001) and QRS score (P<0.001). Patients reaching the primary end point had markedly higher NT-proBNP at each sampling period (P<0.001). NT-proBNP at all time points was the strongest independent predictor of the primary end point in the multivariate model: in the 24 h model, only age and 24 h NT-proBNP (C-index 0.83); and only age, Killip class and NT-proBNP was in the 72 h model (C-index 0.85).
Higher NT-proBNP at 24 h correlated with larger infarct size and worse clinical outcomes. NT-proBNP at baseline, 24 h and 72 h after presentation with acute STEMI, is an independent predictor of a poor outcome and adds clinically useful prognostic information.
虽然利钠肽已在心脏疾病中显示出诊断和预后潜力,但关于它们与心肌梗死的发生及量化之间的关系却知之甚少。本研究探讨了ST段抬高型心肌梗死(STEMI)患者接受直接经皮冠状动脉介入治疗时,连续测定的N末端脑钠肽前体(NT-proBNP)与症状发作持续时间、梗死面积及预后之间的关系。
对心肌梗死血管成形术补体抑制(COMMA)试验中的331例STEMI患者进行了研究,该试验比较了培昔利珠单抗与安慰剂的疗效。在随机分组时、24小时和72小时测量NT-proBNP(pg/mL);在72小时测量肌酸激酶-MB曲线下面积;在出院时评估QRS评分。根据90天的死亡、休克、中风和充血性心力衰竭综合临床结局确定预后。采用多变量逻辑回归对随机分组时、24小时和72小时模型的基线特征进行校正。症状发作时间较长的患者NT-proBNP水平较高(P<0.001),且与梗死面积的测量指标相关,包括曲线下面积(P<0.001)和QRS评分(P<0.001)。达到主要终点的患者在每个采样期的NT-proBNP水平均显著较高(P<0.001)。在多变量模型中,所有时间点的NT-proBNP都是主要终点的最强独立预测因子:在24小时模型中,只有年龄和24小时NT-proBNP(C指数0.83);在72小时模型中,只有年龄、Killip分级和NT-proBNP(C指数0.85)。
24小时时较高的NT-proBNP与较大的梗死面积和较差的临床结局相关。急性STEMI发病后基线、24小时和72小时时的NT-proBNP是不良结局的独立预测因子,并增加了临床上有用的预后信息。